Most Read Articles
Pearl Toh, 4 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 6 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

PCI tied to death, MI, stroke in patients with LMCA, LV dysfunction

26 Sep 2020

Percutaneous coronary intervention (PCI), compared with coronary artery bypass grafting (CABG), in the revascularization of left main coronary artery (LMCA) disease may lead to death, myocardial infarction (MI), or stroke in patients with moderate or severe left ventricular (LV) dysfunction, reveals a study.

“However, the risk for the [composite] outcome was comparable between PCI and CABG in those with normal or mild left ventricular dysfunction,” the investigators said.

Overall, 3,488 patients with LMCA disease who underwent CABG (n=1,355) or PCI (n=2,133) from the IRIS-MAIN registry were included in the analysis. LV function was categorized according to LV ejection fraction (LVEF) as normal function (LVEF ≥55 percent), mild dysfunction (LVEF ≥45 percent to <55 percent), moderate dysfunction (LVEF ≥35 percent to <45 percent), or severe dysfunction (LVEF <35 percent). The primary outcome was a composite of death, MI, or stroke.

Of the patients, 2,641 (75.5 percent) had normal LVEF and 403 (11.6 percent), 260 (7.5 percent), and 184 (5.3 percent) had mild, moderate, and severe LV dysfunction at baseline, respectively.

PCI, compared with CABG, correlated with a higher adjusted risk of the primary outcome in patients with moderate (hazard ratio [HR], 2.23, 95 percent CI, 1.17–4.28) or severe (HR, 2.45, 95 percent CI, 1.27–4.73) dysfunction. On the other hand, PCI and CABG showed similar risks of the composite outcomes in those with normal (HR, 0.80, 95 percent CI, 0.59–1.07) or mild (HR, 1.17, 95 percent CI, 0.63–2.17) dysfunction (pinteraction=0.004).

“LMCA disease is associated with high mortality and morbidity due to a large area of jeopardized myocardium,” the investigators said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 4 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 6 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.